SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-20-023872
Filing Date
2020-04-07
Accepted
2020-04-07 19:31:39
Documents
2
Period of Report
2020-04-07

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 11313
2 POA DOCUMENT poa.txt EX-24.3_909422 3587
  Complete submission text file 0001209191-20-023872.txt   16379
Mailing Address 99 HAYDEN AVENUE, SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER LEXINGTON MA 02421
Business Address 99 HAYDEN AVENUE, SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER LEXINGTON MA 02421 617-513-8774
Keros Therapeutics, Inc. (Issuer) CIK: 0001664710 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O KEROS THERAPEUTICS, INC. 99 HAYDEN AVENUE, SUITE 120, BUILDING E LEXINGTON MA 02421
Business Address
Knowles Julius (Reporting) CIK: 0001808365 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-39264 | Film No.: 20780830